It feels like Boston Scientific (NYSE:BSX) has spent the majority of the past decade in a perpetual limbo of ineffectual turnaround. The shares are down ⅔ over that period, while rivals and peers like Medtronic (NYSE:MDT), St. Jude Medical (NYSE:STJ), and Stryker (NYSE:SYK) have been flat, up 50%, and up 100%, respectively, over the same period. Worse still, Boston Scientific transformed from a market leader to a market laggard and squandered an immeasurable amount of credibility and investor goodwill.
Please follow this link for more:
http://www.massdevice.com/blogs/massdevice/boston-scientific-may-finally-be-right-path-again
MassDevices: Boston Scientific May Finally Be On The Right Path Again
0 comments:
Post a Comment